Endothelial dysfunction in African-Americans

International Journal of Cardiology

Volumn 132, Issue 2, 2009, Pages 157-172

  Patel, Pawan D ^a   Velazquez, Jose L ^a   Arora, Rohit R ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

African Americans; Cardiovascular disease; Endothelial dysfunction

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENDOTHELIN 1; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; NEBIVOLOL; NESIRITIDE; NITRIC OXIDE; PLACEBO; POTASSIUM; PROSTACYCLIN; ROSIGLITAZONE; SELENIUM; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; THROMBOCYTE ACTIVATING FACTOR; VITAMIN D; ZINC;

AFRICAN AMERICAN; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; DYSLIPIDEMIA; EARLY DIAGNOSIS; ENDOTHELIAL DYSFUNCTION; ETHNICITY; FUNCTIONAL ASSESSMENT; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; OBESITY; PERIPHERAL CIRCULATION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SHEAR STRESS; SODIUM INTAKE; STRESS; VASCULAR ENDOTHELIUM;

AFRICAN AMERICANS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; RISK FACTORS;

EID: 59349083530     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.10.007     Document Type: Review

References (231)

1. American Heart Association. Heart disease and stroke statistics-2006 update (2006), American Heart Association, Dallas, Texas
2. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157 (1997) 2413-1446
3. Ferdinand K.C., and Clark L.T. The epidemic of diabetes mellitus and the metabolic syndrome in African Americans. Rev Cardiovasc Med 5 suppl 3 (2004) S28-S33
4. McBean A.M., Li S., Gilbertson D.T., and Collins A.J. Differences in diabetes prevalence, incidence, and mortality among the elderly of four racial/ethnic groups: whites, blacks, Hispanics and Asians. Diabetes Care 27 (2004) 2317-2324
5. Kissela B., Schneider A., Kleindorfer D., et al. Stroke in a biracial population: the excess burden of stroke among blacks. Stroke 35 (2004) 426-431
6. Manhapra A., Canto J.G., Vaccarino V., et al. Relation of age and race with hospital death after acute myocardial infarction. Am Heart J 148 1 (Jul 2004) 92-98
7. Broderick J.P., Brott T., Tomsick T., et al. The risk of subarachnoid and intracerebral hemorrhages in blacks as compared with whites. N Engl J Med 326 11 (Mar 12 1992) 733-736
8. Suresh K. Vascular endothelium: role in health. Indian Heart J 51 (1999) 334-335
9. Fishman A.P. Endothelium: a distributed organ of diverse capabilities. Ann NY Acad Sci 401 (1982) 1-8
10. Furchgott R.F., and Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288 5789 (1980) 373-376
11. Cooke J.P., and Tsao P.S. Cytoprotective effects of nitric oxide. Circulation 88 (1993) 2451-2454
12. 2+ mobilization. Circ Res 81 (1997) 885-892
13. Beckman J.S., and Koppenol W.H. Nitric oxide, superoxide and peroxynitrite. The good, the bad, and ugly. Am J physiol 271 (1996) C1424-C1437
14. Stamler J.S., Singel D.J., and Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science 258 (1992) 1898-1902
15. Michel T. Targeting and translocation of endothelial nitric oxide synthase. Braz J Med Biol Res 32 (1999) 1361-1366
16. Maniatis N.A., Brovkovych V., Allen S.E., et al. Novel mechanism of endothelial nitric oxide synthase activation mediated by caveolae internalization in endothelial cells. Circ Res 99 8 (2006) 870-877
17. Cooke J.P. Asymmetrical dimethylarginine: the Uber marker?. Circulation 109 (2004) 1813-1819
18. Agapitov A.V., and Haynes W.G. Role of endothelin in cardiovascular disease. JRAAS 3 (2002) 1-15
19. Bauersachs J., Popp R., Hecker M., Sauer E., Fleming I., and Busse R. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation 94 (1996) 3341-3347
20. Haddy F.J., Vanhoutte P.M., and Feletou M. Role of potassium in regulating blood flow and blood pressure. Am J Physiol Regul Integr Comp Physiol 290 (2006) R546-R552
21. Inokuchi K., Hirooka Y., Shimokawa H., et al. Role of endothelium-derived hyperpolarizing factor in human forearm circulation. Hypertension 42 5 (Nov 2003) 919-924
22. Hirooka Y., Imaizumi T., Harada S., et al. Endothelium-dependent forearm vasodilation to acetylcholine but not to substance P is impaired in patients with heart failure. J Cardiovasc Pharmacol 20 suppl 12 (1992) S221-S225
23. Mulvihill N.T., Foley J.B., Murphy R.T., et al. Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules. Heart 85 (2001) 623-627
24. Ridker P.M., Rifai N., Rose L., et al. Comparison of C-Reactive protein and low density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
25. Rodriguez L.G., Alfieri A.B., and Cubeddu L.X. Urinary excretion of nitric oxide metabolites in runners, sedentary individuals and patients with coronary artery disease: effects of 42 km marathon, 15 km race and a cardiac rehabilitation program. J Cardiovasc Risk 4 (1997) 367-372
26. Jyrki T., Olli T., and Lance K. Imaging of the endothelial dysfunction in coronary atherosclerosis. Eur J Nucl Med 28 (2001) 1567-1578
27. Ludmer P.L., Selwyn A.P., and Shook T.L. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 315 (1986) 1046-1051
28. Yang Y., and Loscalzo J. Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide. Circulation 101 (2000) 2144-2148
29. Ting H.H., Timimi F.K., and Haley E.A. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia. Circulation 95 (1997) 2617-2622
30. Topper J.N., Cai J., Falb D., and Gimbrone Jr. M.A. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-3, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci U S A 93 (1996) 104-117
31. McLenachan J.M., Vita J., and Fish D.R. Early evidence of endothelial vasodilator dysfunction at coronary branch points. Circulation 82 (1990) 1169-1173
32. Rubanyi G.M., Romero C., and Vanhouette P.M. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol 250 6 Pt 2 (Jun 1986) H1145-H1149
33. Chaveau M., Levy B., and Dessanges J.F. Quantitative doppler blood flow measurement method and in vivo calibration. Cardiovasc Res. 19 (1985) 700-706
34. Thorne S., Mullen M.J., Clarkson P., Donald A.E., and Deanfield J.E. Early endothelial dysfunction in adults at risk for atherosclerosis. Different response to L-arginine. J Am Coll Cardiol 32 (1998) 110-116
35. Sorensen K.E., Celermajer D.S., Georgakopoulos D., Hatcher G., Betteridge D.J., and Deanfield J.E. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest 93 (1994) 50-55
36. Woodman O.L. Modulation of vasoconstriction by endothelium-derived nitric oxide: the influence of vascular disease. Clin Exp Pharmacol Physiol 22 (1995) 585-593
37. Tsurumi Y., Nagashima H., Ichikawa K., Sumiyoshi T., and Hosoda S. Influence of plasma lipoprotein (a) levels on coronary vasomotor response to acetylcholine. J Am Coll Cardiol 26 (1995) 1242-1250
38. Hashimoto M., Akishita M., and Eto M. The impairment of flow-mediated vasodilatation in obese men with visceral fat accumulation. Int J Obes 229 5 (1998) 477-484
39. Steinberg H.O., Chaker H., Leaming R., Johnson A., Brechtel G., and Baron A.D. Obesity/insulin resistance is associated with endothelial dysfunction. J Clin Invest 97 (1996) 2601-2610
40. Suwaidi J.A., Hamasaki S., Higano S.T., Nishimura R.A., Holmes Jr. D.R., and Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101 (2000) 948-954
41. Jeffrey T., Ayan R., and Kathleen A. Peripheral vascular endothelial function testing as a noninvasive indicator of coronary artery disease. J Am Coll Cardiol. 38 (2001) 1843-1849
42. Sorensen K.E., Celermajer D.S., and Spiegalhalter D.S. Non-invasive measurement of endothelium dependent arterial responses in man: accuracy and reproducibility. Br Heart J 74 (1995) 247-253
43. Celermajer D., Sorensen K., and Gooch V. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340 (1992) 1111-1115
44. Bonetti P.O., Barsness G.W., and Keelan P.C. Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol 41 (2003) 1761-1768
45. Cohn J.N. Arterial compliance to stratify cardiovascular risk: more precision in therapeutic decision making. Am J Hypertens 14 (2001) 258S-263S
46. Oliver J.J., and Webb D.J. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler Thromb Vasc Biol 23 (2003) 554-566
47. Perregaux D., Chaudhuri A., Rao S., et al. Brachial vascular reactivity in blacks. Hypertension 36 (2000) 866
48. Campia U., Choucair W.K., Bryant M.B., Waclawiw M.A., Cardillo C., and Panza J.A. Reduced endothelium-dependent and -independent dilation of conductance arteries in African-Americans. J Am Coll Cardiol 40 (2002) 754-760
49. Jones D.S., Andrawis N.S., and Abernethy D.R. Impaired endothelial-dependent forearm vascular relaxation in black Americans. Clin Pharmacol Ther 65 (1999) 408-412
50. D'Agostino Jr. R.B., Burke G., O'Leary D., et al. Ethnic differences in carotid wall thickness. The Insulin Resistance Atherosclerosis Study. Stroke 27 10 (Oct 1996) 1744-1749
51. Lange L.A., Bowden D.W., Langefeld C.D., et al. Heritability of carotid artery intima-media thickness in type 2 diabetes. Stroke 33 (2002) 1876-1881
52. Evans R.R., Phillips B.G., Singh G., Bauman J.L., and Gulati A. Racial and gender differences in Endothelin-1. Am J Cardiol 78 (1996) 486-488
53. Cardillo C., Kilcoyne C.M., Cannon R.O., and Panza J.A. Racial differences in nitric oxide-mediated vasodilator response to mental stress in the forearm circulation. Hypertension 31 (1998) 1235-1239
54. Lang C.C., Stein C.M., Brown R.M., et al. Attenuation of isoproterenol-mediated vasodilatation in blacks. N Engl J Med 333 3 (Jul 20 1995) 155-160
55. Rosenbaum D.A., Pretorius M., Gainer J.V., et al. Ethnicity affects vasodilation, but not endothelial tissue plasminogen activator release, in response to bradykinin. Arterioscler Thromb Vasc Biol 22 6 (Jun 1 2002) 1023-1028
56. Gainer J.V., Stein C.M., Neal T., Vaughan D.E., and Brown N.J. Interactive effect of ethnicity and ACE insertion/deletion polymorphism on vascular reactivity. Hypertension 37 (2001) 46-51
57. Kahn D.F., Dufffy S.J., Tomasian D., et al. Effects of Black race on forearm resistance vessel function. Hypertension 40 (2002) 195
58. Stein C.M., Lang C.C., Nelson R., Brown M., and Wood A.J. Vasodilation in black Americans: attenuated nitric oxide-mediated responses. Clin Pharmacol Ther 62 4 (Oct 1997) 436-443
59. Bransford T.L., St Vrain J.A., and Webb M. Abnormal endothelial function in young African-American females: discordance with blood flow. J Natl Med Assoc 93 4 (Apr 2001) 113-119
60. Loehr L.R., Espeland M.A., Sutton-Tyrrell K., Burke G.L., Crouse III J.R., and Herrington D.M. Racial differences in endothelial function in postmenopausal women. Am Heart J 148 4 (Oct 2004) 606-611
61. Kalinowski L., Dobrucki I.T., and Malinski T. Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases. Circulation 109 (2004) 2511-2517
62. Guzik T.J., West N.E., Black E., et al. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res 86 (2000) E85-E90
63. Marchesi S., Lupattelli G., Sensini A., et al. Racial difference in endothelial function: role of the infective burden. Atherosclerosis 191 1 (Mar 2007) 227-234
64. Mensah G.A., Mokdad A.H., Ford E.S., Greenlund K.J., and Croft J.B. State of disparities in cardiovascular health in the United States. Circulation 111 (2005) 1233-1241
65. MacLeod M.J., and McLay J. Drug treatment of hypertension complicating diabetes mellitus. Drugs 56 (1998) 189-202
66. Bloem L.J., Manatunga A.K., Tewksbury D.A., and Pratt J.H. The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. J Clin Invest 95 3 (Mar 1995) 948-953
67. Caulfield M., Lavender P., Newell-Price J., et al. Linkage of the angiotensinogen gene locus to human essential hypertension in African Caribbeans. J Clin Invest 96 2 (Aug 1995) 687-692
68. Bloem L.J., Manatunga A.K., and Pratt J.H. Racial difference in the relationship of an angiotensin I-converting enzyme gene polymorphism to serum angiotensin I-converting enzyme activity. Hypertension 27 1 (Jan 1996) 62-66
69. Baker E.H., Dong Y.B., Sagnella G.A., et al. Association of hypertension with T594 M mutation in ß-subunit of epithelial sodium channels in black people resident in London. Lancet 351 (1998) 1388-1392
70. Dong Y., Zhu H., Sagnella G.A., Carter N.D., Cook D.G., and Cappuccio F.P. Association between the C825T polymorphism of the G protein ß3-subunit gene and hypertension in blacks. Hypertension 34 (1999) 1193-1196
71. Johnson J.A., Burlew B.S., and Stiles R.N. Racial differences in beta-adrenoceptor-mediated responsiveness. J Cardiovasc Pharmacol 25 1 (Jan 1995) 90-96
72. Stein C.M., Deegan R., and Wood A.J. Lack of correlation between arterial and venous beta-adrenergic receptor sensitivity. Hypertension 29 6 (Jun 1997) 1273-1277
73. Xie H.G., Stein C.M., Kim R.B., et al. Frequency of functionally important beta-2 adrenoceptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals. Pharmacogenetics 9 (1999) 511-516
74. Wood A.J. Variability in beta-adrenergic receptor response in the vasculature:role of receptor polymorphism. J Allergy Clin Immunol 110 (2002) S318-S321 (Suppl)
75. Suthanthiran M., Li B., and Song J.O. Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: a novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci U S A 97 (2000) 3479-3484
76. Kimura M., Cho J.H., Lasker N., and Aviv A. Differences in platelet calcium regulation between African Americans and Caucasians: implications for the predisposition of African Americans to essential hypertension. J Hypertens 12 2 (Feb 1994) 199-207
77. Anderson N.B., Myers H.F., Pickering T., and Jackson J.S. Hypertension in blacks: psychosocial and biological perspectives. J Hypertens 7 3 (Mar 1989) 161-172
78. Calhoun D.A. Hypertension in blacks: socioeconomic stress and sympathetic nervous system activity. Am J Med Sci 304 5 (Nov 1992) 306-311
79. Treiber F.A., Jackson R.W., Davis H., et al. Racial differences in Endothelin-1 at rest and in response to acute stress in adolescent males. Hypertension 35 (2000) 722
80. Ergul S., Parish C.D., Puett D., and Ergul A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension 28 (1996) 652-655
81. Ergul A. Hypertension in black patients: an emerging role of the endothelin system in salt-sensitive hypertension. Hypertension 36 (2000) 62-67
82. Ergul A., Tackett R.L., and Puett D. Distribution of endothelin receptors in saphenous veins of African Americans: implications of racial differences. J Cardiovasc Pharmacol 34 (1999) 327-332
83. Stamler J., Rose G., Eliot P., et al. Findings of the international cooperative INTERSALT study. Hypertension 17 Suppl 1 (1991) 9-15
84. Brier M.E., and Luft F.C. Sodium kinetics in white and black normotensive subjects: possible relevance to salt-sensitive hypertension. Am J Med Sci 307 Suppl 1 (Feb 1994) S38-S42
85. Aviv A., Hollenberg N.K., and Weder A. Urinary potassium excretion and sodium sensitivity in blacks. Hypertension 43 (2004) 707-713
86. Clark L.T. Primary prevention of cardiovascular disease in high-risk patients: physiologic and demographic risk factor differences between African American and white American populations. Am J Med 107 (1999) 22S-24S
87. Calhoun D.A., and Oparil S. Racial differences in the pathogenesis of hypertension. Am J Med Sci 310 (1995) S86-S90
88. He F.J., Markandu N.D., Sagnella G.A., and MacGregor G.A. Importance of the renin system in determining blood pressure fall with salt restriction in black and white hypertensives. Hypertension 32 (1998) 820-824
89. Boddi M., Poggesi L., Coppo M., et al. Human vascular renin-angiotensin system and its functional changes in relation to different sodium intakes. Hypertension 31 (Mar 1998) 836-842
90. Morris Jr. R.C., Sebastian A., Forman A., Tanaka M., and Schmidlin O. Normotensive salt sensitivity: effects of race and dietary potassium. Hypertension 33 (1999) 18-23
91. Sudhir K., Forman A., Yi S.-L., et al. Reduced dietary potassium reversibly enhances vasopressor response to stress in African Americans. Hypertension 29 (1997) 1083-1090
92. Matlou S., Isles G., Higgs A., et al. Potassium supplementation in blacks with mild to moderate essential hypertension. J Hypertension 4 (1986) 61-64
93. Campese V.M., Tawadrous M., Bigazzi R., et al. Salt intake and plasma atrial natriuretic peptide and nitric oxide in hypertension. Hypertension 28 (1996) 335-340
94. Fujiwara N., Osanai T., Kamada T., Katoh T., Takahashi K., and Okumura K. Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: modulation of nitric oxide synthesis by salt intake. Circulation 101 (2000) 856-861
95. Bragulat E., de la Sierra A., Antonio M.T., and Coca A. Endothelial dysfunction in salt-sensitive essential hypertension. Hypertension 37 (2001) 444-448
96. Kielstein J.T., Simmel S., Bode-Boger S.M., et al. Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press Res 27 (2004) 143-147
97. Juonala M., Viikari J.S.A., Alfthan G., et al. Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the cardiovascular risk in Young Finns Study. Circulation 116 (2007) 1367-1373
98. Melikian N., Wheatcroft S.B., Ogah O.S., et al. Asymmetric dimethylarginine and reduced nitric oxide bioavailability in young black African men. Hypertension 49 (2007) 873-877
99. Fang Y., Mu J.-J., He L.-Chong., Wang S.-C., and Liu Z.-Q. Salt loading on plasma asymmetrical dimethylarginine and the protective role of potassium supplement in normotensive salt-sensitive Asians. Hypertension 48 (2006) 724-729
100. Koren M.J., Mensah G.A., Blake J., Laragh J.H., and Devereux R.B. Comparison of left ventricular mass and geometry in black and white patients with essential hypertension. Am J Hypertens 6 10 (Oct 1993) 815-823
101. Mayet J., Shahi M., Foale R.A., Poulter N.R., Sever P.S., and McG Thom S.A. Racial differences in cardiac structure and function in essential hypertension. BMJ 308 6935 (Apr 16 1994) 1011-1014
102. Hinderliter A.L., Light K.C., and Willis IV P.W. Racial differences in left ventricular structure in healthy young adults. Am J Cardiol 69 14 (May 1 1992) 1196-1199
103. Gardin J.M., Brunner D., Schreiner P.J., et al. Demographics and correlates of five-year change in echocardiographic left ventricular mass in young black and white adult men and women: the Coronary Artery Risk Development in Young Adults (CARDIA) study. J Am Coll Cardiol 40 3 (Aug 7 2002) 529-535
104. Hinderliter A.L., Sager A.R., Sherwood A., Light K.C., Girdler S.S., and Willis IV P.W. Ethnic differences in forearm vasodilator capacity. Am J Cardiol 78 2 (Jul 15 1996) 208-211
105. Lapu-Bula R., Ofili E., Oduwole A., et al. Left ventricular structural and geometric relations to endothelium-dependent vasodilatory function: a clue to the hypertensive phenotype in African Americans[abstract]. J Am Soc Echocardiogr 14 (2001) P5-P492
106. Lapu-Bula R., and Ofili E. From hypertension to heart failure: role of nitric oxide-mediated endothelial dysfunction and emerging insights from myocardial contrast echocardiography. Am J Cardiol 99 (2007) 7D-14D [suppl]
107. Houghton J.L., Strogatz D.S., Torosoff M.T., et al. African Americans with LVH demonstrate depressed sensitivity of the coronary microcirculation to stimulated relaxation. Hypertension 42 3 (Sep 2003) 269-276 Epub 2003 Aug 11
108. American Heart Association. African-Americans and congestive diseases (1999), American Heart Association, Dallas, TX
109. Congestive heart failure in the United States: a new epidemic (1996), National Heart, Lung and Blood Institute, Bethesda, MD
110. American Heart Association. 2002 Heart and stroke statistical update, American Heart Association (2002), American Heart Association, Dallas, TX
111. Dries D.L., Exner D.V., Gersh B.J., Cooper H.A., Carson P.E., and Domanski M.J. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 340 (1999) 609-616
112. Afzal A., Ananthasubramaniam K., Sharma N., et al. Racial differences in patients with heart failure. Clin Cardiol 22 (1999) 791-794
113. Mathew J., Davidson S., Narra L., Hafeez T., and Garg R. Etiology and characteristics of congestive heart failure in blacks. Am J Cardiol 78 (1996) 1447-1450
114. Gillum R.F. The epidemiology of cardiovascular disease in black Americans. N Engl J Med 335 (1996) 1597-1599
115. Coughlin S.S., Neaton J.D., Sengupta X., and Kuller L.H. Predictors of mortality from idiopathic dilated cardiomyopathy study: 356,222 men screened for the MRFIT. Am J Epidemiol 139 (1994) 166-172
116. Alexander M., Grumbach K., Remy L., Rowell R., and Massie B.M. Congestive heart failure hospitalizations and survival in California: patterns according to race/ethnicity. Am Heart J 137 (1999) 919-927
117. Bourassa M.G., Gurne O., Bangdiwala S.I., et al. Natural history and patterns of current practice in heart failure. The Studies Of Left Ventricular Dysfunction (SOLVD) Investigators. J Am Coll Cardiol 22 (1993) 14A-19A
118. Deswal A., Petersen N.J., Souchek J., Ashton C.M., and Wray N.P. Impact of race on health care utilization and outcomes in veterans with congestive heart failure. J Am Coll Cardiol 43 5 (Mar 3 2004) 778-784
119. Deswal A., Petersen N.J., Urbauer D.L., Wright S.M., and Beyth R. Racial variations in quality of care and outcomes in an ambulatory heart failure cohort. Am Heart J 152 2 (Aug 2006) 348-354
120. Daniels L.B., Bhalla V., Clopton P., et al. B-type natriuretic peptide (BNP) levels and ethnic disparities in perceived severity of heart failure: results from the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) multicenter study of BNP levels and emergency department decision making in patients presenting with shortness of breath. J Card Fail 12 4 (May 2006) 281-285
121. Lanfear D.E., Stolker J.M., Marsh S., Rich M.W., and McLeod H.L. Genetic variation in the B-type natiuretic peptide pathway affects BNP levels. Cardiovasc Drugs Ther 21 1 (Feb 2007) 55-62
122. Sharma R., and Davidoff M.N. Oxidative stress and endothelial dysfunction in heart failure. Congest Heart Fail 8 3 (May-Jun 2002) 165-172
123. Drexler H., Hayoz D., Münzel T., et al. Endothelial function in chronic congestive heart failure. Am J Cardiol 69 19 (Jun 15 1992) 1596-1601
124. Kubo S.H., Rector T.S., Bank A.J., Williams R.E., and Heifetz S.M. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 84 4 (Oct 1991) 1589-1596
125. Díaz-Vélez C.R., García-Castiñeiras S., Mendoza-Ramos E., and Hernández-López E. Increased malondialdehyde in peripheral blood of patients with congestive heart failure. Am Heart J 131 1 (Jan 1996) 146-152
126. Belch J.J., Bridges A.B., Scott N., and Chopra M. Oxygen free radicals and congestive heart failure. Br Heart J 65 5 (May 1991) 245-248
127. Münzel T., and Harrison D.G. Increased superoxide in heart failure. Circulation 100 (1999) 216-218
128. Carson P., Ziesche S., Johnson G., et al. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail 5 (1999) 178-187
129. Exner D., Dries D.L., Domanski M.J., et al. Lesser response to angiotensin-converting-enzyme inhibitor therapy in blacks as compared to white patients with left ventricular dysfunction. N Engl J Med 344 (2001) 1351-1357
130. Preston R.A., Materson B.J., Reda D.J., et al. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. JAMA 280 (1998) 1168-1172
131. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344 (2001) 1659-1667
132. Yancy C.W., Fowler M.B., Colucci W.S., et al. for the U.S. Carvedilol Heart Failure Study Group. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 344 (2001) 1358-1365
133. Packer M., Fowler M.B., Roecker E.B., et al. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106 (2002) 2194-2199
134. Abraham W.T., Massie B.M., Franciosa J.A., et al. Tolerability, safety, and efficacy of beta-blockade in black patients with heart failure in the community setting: insights from a large prospective beta-blocker registry. Presented at the Heart Failure Society of America 7th Annual Scientific Meeting; September 22, 2003; Las Vegas, Nevada [abstract 348]. J Card Fail 9 suppl 1 (2003) S94
135. Taylor A.L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351 20 (2004) 2049-2057
136. Hare J.M. Nitro-redox balance in the cardiovascular system. N Engl J Med 351 (2004) 2112-2114
137. Cohn J.N., Tam S.W., Anand I.S., Taylor A.L., Sabolinski M.L., and Worcel M. A-HeFT investigators. Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. J Card Fail 13 5 (Jun 2007) 331-339
138. Meis S.B., Schuster D., Gaillard T., and Osei K. Metabolic syndrome in nondiabetic, obese, first-degree relatives of African American patients with type 2 diabetes: African American triglycerides-HDL-C and insulin resistance paradox. Ethn Dis 16 4 (Autumn 2006) 830-836
139. Osei K., Rhinesmith S., Gaillard T., and Schuster D. Is glycosylated hemoglobin A1c a surrogate for metabolic syndrome in nondiabetic, first-degree relatives of African-American patients with type 2 diabetes?. J Clin Endocrinol Metab 88 10 (Oct 2003) 4596-4601
140. Gower B.A., Nagy T.R., and Goran M.I. Visceral fat, insulin sensitivity, and lipids in prepubertal children. Diabetes 48 8 (Aug 1999) 1515-1521
141. Arslanian S.A., Saad R., Lewy V., Danadian K., and Janosky J. Hyperinsulinemia in African-American children: decreased insulin clearance and increased insulin secretion and its relationship in insulin sensitivity. Diabetes 51 (2002) 3014-3019
142. Steinberg H.O., Brechtel G., Johnson A., Fineberg N., and Baron A.D. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 94 3 (Sep 1994) 1172-1179
143. Anderson E.A., Hoffman R.P., Balon T.W., Sinkey C.A., and Mark A.L. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 87 6 (Jun 1991) 2246-2252
144. Duck M.M., and Hoffman R.P. Impaired endothelial function in healthy African-American adolescents compared with Caucasians. J Pediatr 150 4 (Apr 2007) 400-406
145. Zeng G., Nystrom F.H., Ravichandran L.V., et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 101 (2000) 1539-1545
146. Potenza M.A., Marasciulo F.L., Chieppa D.M., et al. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am J Physiol 289 (2005) H813-H822
147. Cusi K., Maezono K., Osman A., et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 105 (2000) 311-320
148. Petrie J.R., Ueda S., Webb D.J., Elliott H.L., and Connell J.M.C. Endothelial nitric oxide production and insulin sensitivity: a physiological link with implications for pathogenesis of cardiovascular disease. Circulation 93 (1996) 1331-1333
149. Steinberg H.O., Chaker H., Leaming R., Johnson A., Brechtel G., and Baron A.D. Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance. J Clin Invest 97 (1996) 2601-2610
150. Lteif A.A., Han K., and Mather K.J. Obesity, insulin resistance, and the metabolic syndrome: determinants of endothelial dysfunction in whites and blacks. Circulation 112 1 (Jul 5 2005) 32-38
151. Stühlinger M.C., Abbasi F., Chu J.W., et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287 (2002) 1420-1426
152. Sydow K., Mondon C.E., and Cooke J.P. Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA. Vascular Medicine vol. 10, No. 2suppl (2005) S35-S43
153. Piatti P.M., Monti L.D., Conti M., et al. Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans. Diabetes 45 (1996) 316-321
154. Mirzamohammadi B., Lteif A., Steinberg H.O., and Baron A.D. Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes. Diabetes 51 (2002) 3517-3523
155. Kumanyika S.K. Obesity in minority populations: an epidemiologic assessment. Obes Res 2 (1994) 166-182
156. Dawson D.A. Ethnic differences in female overweight: data from the 1985 National Health Interview Survey. Am J Public Health 129 (1988) 1376-1379
157. National Center for Health Statistics. Anthropometric reference data & prevalence of overweight United States 1976-80. DHHS publication (PHS) 87-1688. Vital Health Stat 11 (1987) 238
158. Bower J.F., Davis J.M., Hao E., and Barakat H.A. Differences in transport of fatty acids and expression of fatty acid transporting proteins in adipose tissue of obese black and white women. Am J Physiol Endocrinol Metab 290 (2006) E87-E91
159. McConnaughey M.M., Sheets K.A., Davis J., et al. Differences in beta-adrenergic receptor densities in omental and subcutaneous adipose tissue from obese African American and Caucasian women. Metabolism 53 2 (Feb 2004) 247-251
160. Barakat H., Davis J., Lang D., Mustafa S.J., and McConnaughey M.M. Differences in the expression of the adenosine A1 receptor in adipose tissue of obese black and white women. J Clin Endocrinol Metab 91 5 (May 2006) 1882-1886
161. Bush N.C., Darnell B.E., Oster R.A., Goran M.I., and Gower B.A. Adiponectin is lower among African Americans and is independently related to insulin sensitivity in children and adolescents. Diabetes 54 (2005) 2772-2778
162. Nishizawa H., Shimomura I., Kishida K., et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51 (2002) 2734-2741
163. Tan K.C., Xu A., Chow W.S., et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab 89 2 (Feb 2004) 765-769
164. MacLean P., Bower J.F., Vadlamudi S., Green T., and Barakat H.A. Lipoprotein subpopulation distribution in lean, obese and type 2 diabetic women: a comparison of African and Caucasian Americans. Obes Res 8 (2000) 62-70
165. Paultre F., Tuck C.H., Boden-Albala B., et al. Relation of apo(a) size to carotid atherosclerosis in an elderly multiethnic population. Arterioscler Thromb Vasc Biol 21 (2002) 141-146
166. Kraft H.G., Lingenhel A., Kochl S., et al. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary artery disease. Arterioscler Thromb Vasc Biol 16 (1996) 713-719
167. Wu H.D., Berglund L., and Dimayuga C. High lipoprotein(a) levels and small apolipoprotein(a) sizes are associated with endothelial dysfunction in a multiethnic cohort. J Am Coll Cardiol 43 (2004) 1828-1833
168. Marcovina S.M., Albers J.J., Wijsman E., et al. Differences in Lp(a) concentrations and apo(a) polymorphs between black and white Americans. J Lipid Res 37 (1996) 2569-2585
169. Yanoff L.B., Parikh S.J., Spitalnik A., et al. The prevalence of hypovitaminosis D and secondary hyperparathyroidism in obese Black Americans. Clin Endocrinol (Oxf) 64 5 (2006) 523-529
170. Clemens T.L., Adams J.S., Henderson S.L., and Holick M.F. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet 1 8263 (Jan 9 1982) 74-76
171. Wortsman J., Matsuoka L.Y., Chen T.C., Lu Z., and Holick M.F. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 72 (2000) 690-693
172. Harris S.S., and Dawson-Hughes B. Seasonal changes in plasma 25-hydroxyvitamin D concentrations of young American black and white women. Am J Clin Nutr 67 (1998) 1232-1236
173. Moore C.E., Murphy M.M., and Holick M.F. Vitamin D intakes by children and adults in the United States differ among ethnic groups. J Nutr 135 (2005) 2478-2485
174. McCarron D.A., and Morris C.D. The calcium deficiency hypothesis of hypertension. Ann Intern Med 107 (1987) 919-922
175. Scragg R., Jackson R., Holdaway I.M., Lim T., and Beaglehole R. Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. Int J Epidemiol 19 (1990) 559-563
176. Zittermann A., Schleithoff S.S., Tenderich G., Berthold H.K., Korfer R., and Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure?. J Am Coll Cardiol 41 (2003) 105-112
177. Arroyo M., Laguardia S.P., Bhattacharya S.K., et al. Micronutrients in African-Americans with decompensated and compensated heart failure. Transl Res 148 6 (Dec 2006) 301-308
178. Laguardia S.P., Dockery B.K., Bhattacharya S.K., Nelson M.D., Carbone L.D., and Weber K.T. Secondary hyperparathyroidism and hypovitaminosis D in African-Americans with decompensated heart failure. Am J Med Sci 332 3 (Sep 2006) 112-118
179. London G.M., Guérin A.P., Verbeke F.H., et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 18 2 (Feb 2007) 613-620
180. de Lorgeril M., Salen P., Accominotti M., et al. Dietary and blood antioxidants in patients with chronic heart failure. Insights into the potential importance of selenium in heart failure. Eur J Heart Fail 3 6 (Dec 2001) 661-669
181. de Lorgeril, and Salen P. Selenium and antioxidant defenses as major mediators in the development of chronic heart failure. Heart Fail Rev 11 1 (Mar 2006) 13-17
182. Weaver J.A., Maddox J.F., Cao Y.Z., Mullarky I.K., and Sordillo L.M. Increased 15-HPETE production decreases prostacyclin synthase activity during oxidant stress in aortic endothelial cells. Free Radic Biol Med 30 3 (Feb 1 2001) 299-308
183. Kuliczkowski W., Jołda-Mydłowska B., Kobusiak-Prokopowicz M., Antonowicz-Juchniewicz J., and Kosmala W. Effect of heavy metal ions on function of vascular endothelium in patients with ischemic heart disease. Pol Arch Med Wew 111 6 (Jun 2004) 679-685
184. Hennig B., Toborek M., and McClain C.J. Antiatherogenic properties of zinc: implications in endothelial cell metabolism. Nutrition 12 (1996) 711-717
185. Meerarani P., Reiterer G., Toborek M., and Hennig B. Zinc modulates PPARgamma signaling and activation of porcine endothelial cells. J Nutr 133 10 (Oct 2003) 3058-3064
186. Mason J.O. Understanding the disparities in morbidity and mortality among racial and ethnic groups in the United States. Ann Epidemiol 3 (1993) 120-124
187. Howard G., Anderson R.T., Russell G., Howard V.J., and Bruke G.L. Race, socioeconomic status, and cause-specific mortality. Ann Epidemiol 10 (2000) 214-223
188. Rosengren A., Hawken S., Ounpuu S., et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11.119 cases and 13.648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004) 953-962
189. House J.S., Landis K.R., and Umberson D. Social relationships and health. Science 241 (1988) 540-545
190. Wallace R., and Wallace D. Origins of public health collapse in New York City: the dynamics of planned shrinkage, contagious urban decay and social disintegration. Bull N Y Acad Med 66 (1990) 391-434
191. Miller G.J., Kotecha S., Wilkinson W.H., et al. Dietary and other characteristics relevant for coronary heart disease in men of Indian, West Indian and European descent in London. Atherosclerosis 70 (1988) 63-72
192. Kalra L., Rambaran C., and Iveson E. The role of inheritance and environment in predisposition to vascular disease in people of African descent. J Am Coll Cardiol 47 (2006) 1126-1133
193. Brodersen N.H., Steptoe A., Williamson S., and Wardle J. Sociodemographic, developmental, environmental, and psychological correlates of physical activity and sedentary behavior at age 11 to 12. Ann Behav Med 29 (2005) 2-11
194. Wallace Jr. J.M., Bachman J.G., O'Malley P.M., Schulenberg J.E., Cooper S.M., and Johnston L.D. Gender and ethnic differences in smoking, drinking and illicit drug use among Am 8th, 10th and 12th grade students, 1976-2000. Addiction 98 (2003) 225-234
195. Geronimus A.T., Bound J., Waidmann T.A., Hillemeier M.M., and Burns P.B. Excess mortality among blacks and whites in the United States. N Engl J Med 335 21 (1996) 1552-1558
196. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
197. Douglas J.G. Clinical guidelines for the treatment of hypertension in African Americans. Am J Cardiovasc Drugs 5 1 (2005) 1-6
198. Ferdinand K.C., and Saunders E. Hypertension-related morbidity and mortality in African Americans-why we need to do better. J Clin Hypertens (Greenwich) 8 1 Suppl 1 (Jan 2006) 21-30
199. Pickkers P., Hughes A.D., Russel F.G.M., Thien T., and Smits P. Thiazide-induced vasodilation in humans is mediated by potassium channel activation. Hypertension 32 (1998) 1071-1076
200. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2997
201. Agodoa L.Y., Appel L., Bakris G.L., et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 285 (2001) 2719-2728
202. Wright J.T., Bakris G., and Greene T. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA 288 (2002) 2421-2431
203. Bertrand M.E. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. Curr Med Res Opin 20 10 (Oct 2004) 1559-1569
204. Delles C., Schneider M.P., John S., Gekle M., and Schmieder R.E. Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension. Am J Hypertens 15 (2002) 590-593
205. Chobanian A.V., Haudenschild C.C., Nickerson C., et al. Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Hypertension 20 (1992) 473-477
206. Jawa A., Nachimuthu S., Pendergrass M., Asnani S., and Fonseca V. Impaired vascular reactivity in African-American patients with type 2 diabetes mellitus and microalbuminuria or proteinuria despite angiotensin-converting enzyme inhibitor therapy. J Clin Endocrinol Metab 91 1 (Jan 2006) 31-35
207. von Fallois J., and Faulhaber H.D. Nebivolol, a beta blocker of the 3rd generation: modern therapy of arterial hypertension. Results of a multicenter observation study [article in German]. Schweiz Rundsch Med Praxis 90 (2001) 435-441
208. Georgescu A., Popov D., Dragan E., Dragomir E., and Badila E. Protective effects of nebivolol and reversal of endothelial dysfunction in diabetes associated with hypertension. Eur J Pharmacol 570 1-3 (Sep 10 2007) 149-158
209. Mason R.P., Kalinowski L., Jacob R.F., Jacoby A.M., and Malinski T. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation 112 24 (Dec 13 2005) 3795-3801
210. Durand J.B. Heart failure management in African Americans: meeting the challenge. J Clin Hypertens (Greenwich) 6 4 Suppl 1 (Apr 2004) 42-47
211. Ruffolo R.R., and Feuerstein G.Z. Pharmacology of Carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. Cardiovasc Drugs Ther 11 (1997) 247-256
212. Drexler H., Kurz S., Jeserich M., Münzel T., and Hornig B. Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure. Am J Cardiol 76 (1995) 13E-18E
213. Schäfer A., Fraccarollo D., Tas P., Schmidt I., Ertl G., and Bauersachs J. Endothelial dysfunction in congestive heart failure: ACE inhibition vs. angiotensin II antagonism. Eur J Heart Fail 6 2 (2004) 151-159
214. Bauersachs J., Heck M., Fraccarollo D., et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 39 2 (2002) 351-358
215. Giugliano D., Acampora R., Marfella R., et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized, controlled trial. Ann Intern Med 126 (1997) 955-959
216. Bakris G.L., Fonseca V., Katholi R.E., et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292 (2004) 2227-2236
217. Jacob S., Rett K., Wickmayr M., Agrawal B., Augustin H.J., and Dietze G.-J. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 14 (1996) 489-494
218. Sherwood A., May C.W., Siegel W.C., and Blumenthal J.A. Ethnic differences in hemodynamic responses to stress in hypertensive men and women. Am J Hypertens 8 6 (Jun 1995) 552-557
219. Sudhir K., Forman A., Yi S.L., et al. Reduced dietary potassium reversibly enhances vasopressor response to stress in African Americans. Hypertension 29 (1997) 1083-1090
220. Gokce N., Holbrook M., Duffy S.J., et al. Effects of race and hypertension on flow-mediated and nitroglycerin-mediated dilation of the brachial artery. Hypertension 38 6 (Dec 1 2001) 1349-1354
221. Ferdinand K.C. African American heart failure trial: role of endothelial dysfunction and heart failure in African Americans. Am J Cariol 99 (2007) 3D-6D [suppl]
222. Arora R.R. Nesiritide: trials and tribulations. J Cardiovasc Pharmacol Ther 11 3 (Sep 2006) 165-169
223. Wang T., Yan M., Li J., and Zheng X. The role of iNOS-derived NO in the antihypertrophic actions of B-type natriuretic peptide in neonatal rat cardiomyocytes. Mol Cell Biochem 302 1-2 (Aug 2007) 169-177
224. Matsumoto T., Wada A., Tsutamoto T., et al. Vasorelaxing effects of atrial and brain natriuretic peptides on coronary circulation in heart failure. Am J Physiol 276 (1999) H1935-H1942
225. Khush K.K., De Marco T., Vakharia K.T., et al. Nesiritide acutely increases pulmonary and systemic levels of nitric oxide in patients with pulmonary hypertension. J Card Fail 12 7 (Sep 2006) 507-513
226. Clark L.T., and El-Atat F. Metabolic syndrome in African Americans: implications for preventing coronary heart disease. Clin Cardiol 30 4 (Apr 2007) 161-164
227. Kelly A.S., Thelen A.M., Kaiser D.R., Gonzalez-Campoy J.M., and Bank A.J. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. Vasc Med 12 4 (2007) 311-318
228. Houghton J.L., Philbin E.F., Strogatz D.S., et al. The presence of African American race predicts improvement in coronary endothelial function after supplementary l-arginine. J Am Coll Cardiol 39 8 (Apr 17 2002) 1314-1322
229. Schneider R.H., Alexander C.N., Staggers F., et al. A randomized controlled trial of stress reduction in African Americans treated for hypertension for over one year. Am J Hypertens 18 1 (Jan 2005) 88-98
230. Jayadevappa R., Johnson J.C., Bloom B.S., et al. Effectiveness of transcendental meditation on functional capacity and quality of life of African Americans with congestive heart failure: a randomized control study. Ethn Dis 17 1 (Winter 2007) 72-77
231. Pérez-Castrillón J.L., Vega G., Abad L., et al. Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol 99 7 (Apr 1 2007) 903-905